Reader in Pharmacogenetics, University of Liverpool
Ana’s research over the last 10 years has been focused on molecular pharmacology and pharmacogenetics. She has been working on several projects on identification of genetic predisposing factors for adverse drug reactions. She has also developed an interest in bioinformatics and population statistical analyses. Currently, her research in cardiovascular pharmacology aims at investigating predisposing genetic factors to statin-induced myopathy and angiotensin-converting-enzyme (ACE) inhibitor-induced angioedema utilizing next generation sequencing strategy. She is also involved in public health research via the National Institute of Health Research Collaboration for Leadership in Applied Health Research and Care North West Coast (CLAHRC NWC), where she is a co-lead for the Delivering Personalised Health and Care theme. The overarching aim of the programme is to tackle health inequalities. Within CLAHRC the project on genotype guided dosing of warfarin is being implemented into clinical practice.